Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Trimmed by Clifford Swan Investment Counsel LLC

Clifford Swan Investment Counsel LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 12.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,853 shares of the biopharmaceutical company's stock after selling 7,361 shares during the period. Clifford Swan Investment Counsel LLC's holdings in Gilead Sciences were worth $5,922,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Bridgewater Associates LP grew its holdings in shares of Gilead Sciences by 122.7% in the fourth quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock worth $42,577,000 after purchasing an additional 253,994 shares during the last quarter. Nissay Asset Management Corp Japan ADV grew its position in shares of Gilead Sciences by 5.2% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock worth $26,750,000 after buying an additional 14,009 shares during the last quarter. Golden State Wealth Management LLC increased its stake in shares of Gilead Sciences by 14.5% during the first quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock valued at $97,000 after buying an additional 109 shares during the period. Ontario Teachers Pension Plan Board raised its holdings in shares of Gilead Sciences by 54.6% during the fourth quarter. Ontario Teachers Pension Plan Board now owns 37,051 shares of the biopharmaceutical company's stock valued at $3,422,000 after acquiring an additional 13,086 shares in the last quarter. Finally, Mufg Securities Americas Inc. purchased a new stake in Gilead Sciences in the fourth quarter worth $1,699,000. Institutional investors own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on GILD shares. Morgan Stanley lifted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Cantor Fitzgerald assumed coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective on the stock. Oppenheimer reduced their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Nine equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences currently has an average rating of "Moderate Buy" and an average target price of $111.38.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the sale, the insider owned 121,152 shares in the company, valued at $13,026,263.04. This trade represents a 18.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $111.03, for a total transaction of $277,575.00. Following the completion of the sale, the chief financial officer directly owned 162,610 shares in the company, valued at $18,054,588.30. This represents a 1.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 72,000 shares of company stock valued at $7,844,775. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD traded up $1.89 during midday trading on Tuesday, hitting $110.17. 4,487,230 shares of the stock were exchanged, compared to its average volume of 7,644,095. Gilead Sciences, Inc. has a twelve month low of $70.78 and a twelve month high of $119.96. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. The company has a 50 day moving average price of $108.81 and a 200-day moving average price of $105.35. The stock has a market cap of $137.04 billion, a P/E ratio of 23.19, a PEG ratio of 0.70 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. Gilead Sciences's revenue was down .3% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.32) EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.